| Cash Flow | 2025-07-31 |
|---|---|
| Net loss | -100,361 |
| Stock-based compensation | 30,680 |
| Depreciation and amortization | 44,049 |
| Amortization of operating lease right-of-use | 125,850 |
| Reinvested interests | 185,746 |
| Decrease in accounts receivable | -551,482 |
| Decrease (increase) in other assets | 27,903 |
| Decrease in liabilities | -932,603 |
| Net cash provided by (used in) operating activities | -494,552 |
| Acquisition of property and equipment | 6,294 |
| Marketable securities settlement (investment), net | 603,432 |
| Net cash provided by (used in) investing activities | -609,726 |
| Repurchase of common stock | 22,241 |
| Cash dividends paid to shareholders | 1,719,918 |
| Net cash used in financing activities | -1,742,159 |
| Effect of exchange rate changes on cash | 36,833 |
| Net increase (decrease) in cash and cash equivalents | -2,809,604 |
Pharma-Bio Serv, Inc. (PBSV)
Pharma-Bio Serv, Inc. (PBSV)